High content screen microscopy analysis of Aβ1–42-induced neurite outgrowth reduction in rat primary cortical neurons: Neuroprotective effects of α7 neuronal nicotinic acetylcholine receptor ligands
暂无分享,去创建一个
Murali Gopalakrishnan | Mark E. Schurdak | Min Hu | Jinhe Li | M. Schurdak | M. Gopalakrishnan | P. Puttfarcken | M. Hu | R. E. Kouhen | Jinhe Li | Pamela S. Puttfarcken | Rachid El Kouhen | Min Hu
[1] A. Nordberg,et al. Effect of Subchronic Treatment of Memantine, Galantamine, and Nicotine in the Brain of Tg2576 (APPswe) Transgenic Mice , 2006, Journal of Pharmacology and Experimental Therapeutics.
[2] D. Mash,et al. Characterization of l‐[3H]Nicotine Binding in Human Cerebral Cortex: Comparison Between Alzheimer's Disease and the Normal , 1986, Journal of neurochemistry.
[3] R. Kayed,et al. Soluble Aβ oligomers ultrastructurally localize to cell processes and might be related to synaptic dysfunction in Alzheimer's disease brain , 2005, Brain Research.
[4] R. Papke,et al. Neuroprotective and memory-related actions of novel alpha-7 nicotinic agents with different mixed agonist/antagonist properties. , 1998, The Journal of pharmacology and experimental therapeutics.
[5] M. Rowan,et al. The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. , 2005, Biochemical Society transactions.
[6] S. Shaw,et al. Janus Kinase 2, an Early Target of α7 Nicotinic Acetylcholine Receptor-mediated Neuroprotection against Aβ-(1–42) Amyloid* , 2002, The Journal of Biological Chemistry.
[7] T. Morgan,et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[8] J. Buccafusco,et al. Relationship between the increased cell surface α7 nicotinic receptor expression and neuroprotection induced by several nicotinic receptor agonists , 2001, Journal of neuroscience research.
[9] M. Gallagher,et al. A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.
[10] G. Wilcock,et al. The cholinergic hypothesis of Alzheimer’s disease: a review of progress , 1999, Journal of neurology, neurosurgery, and psychiatry.
[11] C. Lemere,et al. Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans. , 2006, Rejuvenation research.
[12] Edward D. Levin,et al. Nicotinic and muscarinic interactions and choice accuracy in the radial-arm maze , 1991, Brain Research Bulletin.
[13] D. Selkoe. Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. , 2002, The Journal of clinical investigation.
[14] P. Lee,et al. Smoking and Alzheimer's disease: a review of the epidemiological evidence. , 1994, Neuroepidemiology.
[15] M. Albert,et al. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. , 1989, JAMA.
[16] R. Papke,et al. Characterization of the neuroprotective and toxic effects of α7 nicotinic receptor activation in PC12 cells , 1999, Brain Research.
[17] J. Miguel-Hidalgo,et al. Neuroprotection by memantine against neurodegeneration induced by β-amyloid(1–40) , 2002, Brain Research.
[18] W. K. Cullen,et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.
[19] L. M. Espinoza-Fonseca,et al. Molecular docking of four β-amyloid1–42 fragments on the α7 nicotinic receptor: delineating the binding site of the Aβ peptides , 2004 .
[20] D. Westaway,et al. Interactions between β-amyloid and central cholinergic neurons: implications for Alzheimer’s disease , 2004 .
[21] R. Papke,et al. Multiple calcium channels and kinases mediate α7 nicotinic receptor neuroprotection in PC12 cells , 2005, Journal of neurochemistry.
[22] A. Nordberg,et al. Protein and mRNA levels of nicotinic receptors in brain of tobacco using controls and patients with Alzheimer's disease , 2003, Neuroscience.
[23] N. C. D. Fiebre,et al. The α7 nicotinic acetylcholine receptor-selective antagonist, methyllycaconitine, partially protects against β-amyloid1–42 toxicity in primary neuron-enriched cultures , 2004, Brain Research.
[24] Yun Wang,et al. Mediation of BMP7 neuroprotection by MAPK and PKC IN rat primary cortical cultures , 2004, Brain Research.
[25] Dominic M. Walsh,et al. Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease , 2004, Neuron.
[26] R. Malinow,et al. APP Processing and Synaptic Function , 2003, Neuron.
[27] A. Nordberg,et al. Reduced levels of Aβ 40 and Aβ 42 in brains of smoking controls and Alzheimer's patients , 2004, Neurobiology of Disease.
[28] L. Mucke,et al. SIRT1 Protects against Microglia-dependent Amyloid-β Toxicity through Inhibiting NF-κB Signaling* , 2005, Journal of Biological Chemistry.
[29] John M. Lee,et al. Pharmacological Drug Treatment of Alzheimer Disease: The Cholinergic Hypothesis Revisited , 1998, Journal of neuropathology and experimental neurology.
[30] D. Price,et al. Mutant genes in familial Alzheimer's disease and transgenic models. , 1998, Annual review of neuroscience.
[31] S. Shimohama,et al. Nicotinic receptor stimulation protects neurons against β‐amyloid toxicity , 1997 .
[32] P. A. Peterson,et al. β-Amyloid1–42 Binds to α7 Nicotinic Acetylcholine Receptor with High Affinity , 2000, The Journal of Biological Chemistry.
[33] C. Finch,et al. Synaptic Targeting by Alzheimer's-Related Amyloid β Oligomers , 2004, The Journal of Neuroscience.
[34] J. Corwin,et al. Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer’s disease , 1999, Psychopharmacology.
[35] Mark Bowlby,et al. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[36] Kang Hu,et al. High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation , 2000, The Journal of Neuroscience.
[37] S. Wonnacott,et al. Nicotine activates the extracellular signal‐regulated kinase 1/2 via the α7 nicotinic acetylcholine receptor and protein kinase A, in SH‐SY5Y cells and hippocampal neurones , 2002, Journal of neurochemistry.
[38] P. Keller,et al. Globular amyloid β‐peptide1−42 oligomer − a homogenous and stable neuropathological protein in Alzheimer's disease , 2005 .
[39] A. Nordberg,et al. Expression of nicotinic receptors on primary cultures of rat astrocytes and up-regulation of the α7, α4 and β2 subunits in response to nanomolar concentrations of the β-amyloid peptide1–42 , 2005, Neurochemistry International.
[40] D Bertrand,et al. Nicotinic acetylcholine receptors as drug targets. , 2004, Current drug targets. CNS and neurological disorders.
[41] S. Gauthier,et al. Comparative Alterations of Nicotinic and Muscarinic Binding Sites in Alzheimer's and Parkinson's Diseases , 1992, Journal of neurochemistry.
[42] C. Hama,et al. Microglial α7 nicotinic acetylcholine receptors drive a phospholipase C/IP3 pathway and modulate the cell activation toward a neuroprotective role , 2006, Journal of neuroscience research.
[43] Brett Chromy,et al. Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus , 2002, Brain Research.
[44] D. Donnelly-roberts,et al. In vitro neuroprotective properties of the novel cholinergic channel activator (ChCA), ABT-418 , 1996, Brain Research.
[45] H. Ogura,et al. Protective effect of donepezil against Aβ(1-40) neurotoxicity in rat septal neurons , 2005, Brain Research.
[46] J. R. James,et al. Genetic and environmental aspects of the role of nicotinic receptors in neurodegenerative disorders: Emphasis on Alzheimer's disease and Parkinson's disease , 1995, Behavior genetics.
[47] D. L. Taylor,et al. Advances in high content screening for drug discovery. , 2003, Assay and drug development technologies.
[48] E. Wong,et al. Discovery and structure-activity relationship of quinuclidine benzamides as agonists of alpha7 nicotinic acetylcholine receptors. , 2005, Journal of medicinal chemistry.
[49] D. Small,et al. Alpha7-nicotinic acetylcholine receptors mediate an Abeta(1-42)-induced increase in the level of acetylcholinesterase in primary cortical neurones. , 2004, Journal of neurochemistry.
[50] D. Murphy,et al. Neuroendocrine, physiologic, and behavioral responses following intravenous nicotine in nonsmoking healthy volunteers and in patients with alzheimer's disease , 1990, Psychoneuroendocrinology.